Schering AG Making Oncology A Primary Focus; Dermatology Unit Will Become Separate Entity
This article was originally published in The Pink Sheet Daily
Executive Summary
Berlex’ German parent says the new focus will help it exploit the potential of a Phase III angiogenesis inhibitor under development with Novartis. Portfolio restructuring includes termination of R&D in cardiovascular and CNS areas, except for multiple sclerosis and Parkinson’s disease.